Advertisement

PharmacoEconomics

, Volume 31, Issue 1, pp 15–24 | Cite as

Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma

A NICE Single Technology Appraisal
  • Mary KilonzoEmail author
  • Jenni Hislop
  • Andrew Elders
  • Cynthia Fraser
  • Donald Bissett
  • Samuel McClinton
  • Graham Mowatt
  • Luke Vale
Review Article

Abstract

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of pazopanib hydrochloride (GlaxoSmithKline) to submit evidence of the clinical and cost effectiveness of the drug for the first-line treatment of advanced and/or metastatic renal cell carcinoma, as part of the Institute’s single technology appraisal (STA) process. The Aberdeen Health Technology Assessment Group were commissioned to act as the Evidence Review Group (ERG). This article provides a description of the company submission, the ERG review and NICE’s subsequent decisions. The objective of this paper is to summarize the independent review and critique of the evidence submitted for the consideration of the NICE Appraisal Committee and NICE’s subsequently issued guidance. The ERG produced a critical review of the evidence for the clinical and cost effectiveness of the technology based upon the manufacturer’s submission to NICE. The ERG also independently searched for relevant evidence and modified the manufacturer’s decision analytic model to examine the impact of altering some of the key assumptions. For progression-free survival (PFS), there was a statistically significant longer survival for pazopanib compared with placebo (as assessed by the ERG, based upon the original manufacturer submission with a clinical cut-off date of 23 May 2008) [median 11.1 vs. 2.8 months; hazard ratio (HR) 0.40; 95 % CI 0.27, 0.60]. Data from the indirect comparison suggested that pazopanib had a greater survival than interferon alpha (IFN-α) [HR 0.512; 95 % CI 0.326, 0.802] but provided no evidence of any difference compared with sunitinib (HR 0.949; 95 % CI 0.575, 1.568). With regard to overall survival, 64 % (n = 99) of patients in the pazopanib arm and 63 % (n = 49) of patients in the placebo arm had died and a total of 51 % (n = 40) of placebo patients had crossed over to receive pazopanib. Although data were provided on an intention-to-treat basis, crossover between therapies made such data difficult to interpret. There was no evidence of any statistically significant difference between pazopanib and best supportive care (HR 0.501; 95 % CI 0.136, 2.348). In the indirect comparison, there were no statistically significant differences between pazopanib and IFN-α (HR 0.627; 95 % CI 0.173, 2.269) or between pazopanib and sunitinib (HR 0.969; 95 % CI 0.359, 2.608). Based upon the work presented including a 12.5 % discount for pazopanib, sunitinib was extendedly dominated by a combination of pazopanib and IFN-α. As a consequence, the incremental cost per QALY for pazopanib versus IFN-α was £38,925. The results were not greatly altered over the range of univariate deterministic sensitivity analyses conducted by the manufacturer but pair-wise probabilistic sensitivity analyses suggested that given a threshold value of £30,000, there is a 54 % probability that pazopanib was preferred to sunitinib, 40 % chance against IFN-α and 47 % chance against best supportive care. The Appraisal Committee concluded that pazopanib should be recommended as a first-line treatment option for people with advanced renal cell carcinoma who have not received prior cytokine therapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and if the manufacturer provides pazopanib with a 12.5 % discount on the list price and provides a possible future rebate linked to the outcome of the head-to-head COMPARZ trial, as agreed under the terms of the patient access scheme and to be confirmed when the COMPARZ trial data are made available.

Keywords

Overall Survival Sunitinib Pazopanib Indirect Comparison Good Supportive Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number 08/220/01) and will be published as part of a compendium of ERG articles in Health Technology Assessment (HTA). See the HTA programme website for further project information (http://www.hta.ac.uk). This summary of the ERG report was compiled after the Appraisal Committee’s review. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Department of Health. Further acknowledgements are detailed in the ERG report [2]. This summary has not been externally peer reviewed by PharmacoEconomics.

Conflicts of interest

The authors declare no conflicts of interest.

Author contributions

Mary Kilonzo and Luke Vale conducted the critique of the manufacturer’s economic evaluation. Jenni Hislop and Graham Mowatt critiqued the manufacturer’s submission of effectiveness evidence. Donald Bissett and Samuel McClinton provided clinical advice and drafted the background and critique of the manufacturer’s decision problem. Andrew Elders critiqued the statistical methods used. Cynthia Fraser conducted the literature searches and critiqued the methods used for identifying relevant literature. All authors commented on drafts of the report. Mary Kilonzo can act as a guarantor for the overall content.

References

  1. 1.
    National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. London: NICE; 2009. http://www.nice.org.uk/media/42D/B3/STAGuideLrFinal.pdf. Accessed 11 Oct 2011.
  2. 2.
    National Institute for Health and Clinical Excellence. Renal cell carcinoma (first line metastatic): pazopanib. London: NICE; 2011. http://guidance.nice.org.uk/TA/WaveCRS1/46. Accessed 12 Oct 2011.
  3. 3.
    Cancer Research UK. Kidney cancer statistics: London: Cancer Research UK; 2010. http://info.cancerresearchuk.org/cancerstats/types/kidney/index.htm. Accessed 10 Oct 2011.
  4. 4.
    Beisland C, Medby PC, Beisland HO. Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. Scand J Urol Nephrol. 2002;36:414–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Bretheau D, Lechevallier E, Eghazarian C, Grisoni V, Coulange C. Prognostic significance of incidental renal cell carcinoma. Eur Urol. 1995;27:319–23.PubMedGoogle Scholar
  6. 6.
    National Institute for Health and Clinical Excellence. Renal cell carcinoma-sunitinib: guidance [clinical guideline no. TA169]. London: NICE; 2009. http://guidance.nice.org.uk/TA169/Guidance. Accessed 02 Oct 2011.
  7. 7.
    National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 01 Oct 2011.
  8. 8.
    Huston TE, Figlin R, Tabesh M. Sunitinib-associated changes in left ventricular ejection fraction (LVEF) in treatment-naive patients with metastatic renal cell carcinoma (mRCC) [abstract no. 370]. ASCO Genitourinary Cancer Symposium, 5–7 Mar 2010, San Francisco.Google Scholar
  9. 9.
    Hawkins RE. Renal cancer quality of life (QOL) in treatment-naive and cytokine pre-treated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind placebo controlled trial. Eur J Cancer Suppl. 2009;7:428–9.CrossRefGoogle Scholar
  10. 10.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Hancock B, Griffiths G, Ritchie A, Oliver R, Gore M, Mead G. Updated results of the MRC randomised controlled trial of alpha interferon vs MPA in patients with metastatic renal carcinoma. Proc Am Soc Clin Oncol 2000; 19: abstract 1336.Google Scholar
  12. 12.
    Negrier SP. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007;110:2468–77.PubMedCrossRefGoogle Scholar
  13. 13.
    Steineck G, Strander H, Carbin BE, Borgstrom E, Wallin L, Achtnich U, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: a randomized trial. Acta Oncol. 1990;29:155–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859–67.PubMedGoogle Scholar
  15. 15.
    Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology. 1995;45:758–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–40.PubMedGoogle Scholar
  17. 17.
    Kaplan ER, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  18. 18.
    Cox DR. Regression models and life-tables. J Roy Stat Soc B. 1972;34:187–220.Google Scholar
  19. 19.
    Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56:779–88.PubMedCrossRefGoogle Scholar
  20. 20.
    Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods. 1991;20:2609–31.CrossRefGoogle Scholar
  21. 21.
    GlaxoSmithKline. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [ClinicalTrials.gov identifier NCT00720941]. Bethesda: NLM; 2010. http://clinicaltrials.gov/ct2/show/NCT00720941?term=NCT00720941&rank=1. Accessed 01 Oct 2011.
  22. 22.
    GlaxoSmithKline. Patient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (PISCES) [ClinicalTrials.gov identifier NCT01064310]. Bethesda: NLM; 2010. http://clinicaltrials.gov/ct2/show/NCT01064310?term=NCT01064310&rank=1. Accessed 01 Oct 2011.
  23. 23.
    Robins JM. Analytic methods for estimating HIV treatment and cofactor effects. In: Ostrow DG, Kessler R, editors. Methodological issues of AIDS mental health research. New York: Plenum Publishing; 1993. p. 213–90.Google Scholar
  24. 24.
    Berry G, Kitchin RM, Mock RA. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med. 1991;10:749–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics. 2010;28(5):347–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(5):351–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Bagust A, Greenhalgh J, Boland A. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(6):439–48.PubMedCrossRefGoogle Scholar
  28. 28.
    Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(2):133–40.PubMedCrossRefGoogle Scholar
  29. 29.
    Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(11):951–61.PubMedCrossRefGoogle Scholar
  30. 30.
    Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(12):1051–62.PubMedCrossRefGoogle Scholar
  31. 31.
    McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(1):35–46.PubMedCrossRefGoogle Scholar
  32. 32.
    Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(2):137–46.PubMedCrossRefGoogle Scholar
  33. 33.
    Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(4):257–70.PubMedCrossRefGoogle Scholar
  34. 34.
    Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(6):483–95.PubMedCrossRefGoogle Scholar
  35. 35.
    Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, et al. Omalizumab for severe persistent asthma in children aged 6–11 years: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(11):991–1004.PubMedCrossRefGoogle Scholar
  36. 36.
    Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(12):1119–32.PubMedCrossRefGoogle Scholar
  37. 37.
    Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation: a NICE single technology appraisal. Pharmacoeconomics. In press.Google Scholar
  38. 38.
    Simpson EL, Fitzgerald P, Evans P, et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal. Pharmacoeconomics. In press.Google Scholar
  39. 39.
    Armstrong N, Manuela J, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics. In press.Google Scholar
  40. 40.
    Tosh J, Archer R, Davis S, et al. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs: a NICE single technology appraisal. Pharmacoeconomics. In press.Google Scholar
  41. 41.
    Kearns B, Lloyd-Jones M, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics. In press.Google Scholar
  42. 42.
    Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, et al. Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: a single technology appraisal. Southampton: Health Technology Assessment Programme; 2010.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  • Mary Kilonzo
    • 1
    Email author
  • Jenni Hislop
    • 2
  • Andrew Elders
    • 2
  • Cynthia Fraser
    • 2
  • Donald Bissett
    • 3
  • Samuel McClinton
    • 4
  • Graham Mowatt
    • 2
  • Luke Vale
    • 1
    • 2
  1. 1.Health Economics Research Unit, Institute of Applied Health SciencesUniversity of Aberdeen, Polwarth Building, ForesterhillAberdeenUK
  2. 2.Health Services Research, Unit Institute of Applied Health SciencesUniversity of AberdeenAberdeenUK
  3. 3.Department of Clinical OncologyAberdeen Royal InfirmaryAberdeenUK
  4. 4.Department of UrologyAberdeen Royal InfirmaryAberdeenUK

Personalised recommendations